HC Wainwright Analysts Raise Earnings Estimates for MBOT

Key Points

• HC Wainwright has increased its Q3 2025 EPS estimate for Microbot Medical to ($0.07), up from the prior estimate of ($0.08).
• The company reported a quarterly loss of ($0.10) per share, missing the consensus estimate of ($0.08) by ($0.02).
• Current consensus rating for Microbot Medical is a "Buy" with a price target of $9.00 according to MarketBeat.com.

Microbot Medical Inc. (NASDAQ:MBOT - Free Report) - Research analysts at HC Wainwright boosted their Q3 2025 earnings estimates for shares of Microbot Medical in a research report issued on Wednesday, August 20th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will earn ($0.07) per share for the quarter, up from their previous forecast of ($0.08). The consensus estimate for Microbot Medical's current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Microbot Medical's Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.34) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.05) EPS and FY2026 earnings at ($0.25) EPS.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.02).

Several other research firms have also issued reports on MBOT. Wall Street Zen upgraded shares of Microbot Medical from a "sell" rating to a "hold" rating in a research report on Saturday, June 14th. Zacks Research lowered shares of Microbot Medical from a "strong-buy" rating to a "hold" rating in a research report on Thursday. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $9.00.

Microbot Medical Trading Up 8.1%

Shares of NASDAQ:MBOT traded up $0.29 on Friday, reaching $3.85. 5,484,285 shares of the company's stock were exchanged, compared to its average volume of 2,611,637. The company has a fifty day moving average of $2.72 and a 200-day moving average of $2.30. Microbot Medical has a twelve month low of $0.82 and a twelve month high of $3.94. The company has a market capitalization of $175.37 million, a price-to-earnings ratio of -6.64 and a beta of 1.15.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. XTX Topco Ltd purchased a new position in Microbot Medical during the second quarter worth about $43,000. American Century Companies Inc. purchased a new stake in shares of Microbot Medical during the 2nd quarter valued at approximately $32,000. DNB Asset Management AS lifted its stake in shares of Microbot Medical by 67.9% during the 2nd quarter. DNB Asset Management AS now owns 192,786 shares of the biotechnology company's stock valued at $486,000 after buying an additional 77,965 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Microbot Medical by 24.7% during the 2nd quarter. Geode Capital Management LLC now owns 395,039 shares of the biotechnology company's stock valued at $996,000 after buying an additional 78,121 shares in the last quarter. Finally, Lazari Capital Management Inc. purchased a new stake in Microbot Medical in the 2nd quarter worth approximately $54,000. 16.30% of the stock is currently owned by institutional investors and hedge funds.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.